scholarly journals Iron deficiency anemia in elderly patients with kyphosis with reference to iron absorption.

1987 ◽  
Vol 24 (5) ◽  
pp. 444-447
Author(s):  
Kazuo Kubota ◽  
Jun-ichi Tamura ◽  
Takuo Shirakura ◽  
Kyoumi Nakazato ◽  
Toshio Sakurai
Keyword(s):  
Iron Deficiency ◽  
Elderly Patients ◽  
Iron Deficiency Anemia ◽  
Iron Absorption ◽  
Deficiency Anemia

scholarly journals Effect of green tea on iron absorption in elderly patients with iron deficiency anemia.

1990 ◽  
Vol 27 (5) ◽  
pp. 555-558 ◽  
Author(s):  
Kazuo Kubota ◽  
Toshio Sakurai ◽  
Kyoumi Nakazato ◽  
Toyoho Morita ◽  
Takuo Shirakura
Keyword(s):  
Iron Deficiency ◽  
Elderly Patients ◽  
Green Tea ◽  
Iron Deficiency Anemia ◽  
Iron Absorption ◽  
Deficiency Anemia

scholarly journals IRON ABSORPTION AND RESPONSE TO ORAL IRON THERAPY IN IRON DEFICIENCY ANEMIA ASSOCIATED TO ASYMPTOMATIC GIARDIASIS.

1993 ◽  
Vol 33 (6) ◽  
pp. 661-661
Author(s):  
Helena U Suzuki ◽  
Mauro B Morais ◽  
Jose N Corral ◽  
Ulisses Fagundes-Neto ◽  
Nelson L Machado
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Iron Absorption ◽  
Oral Iron ◽  
Iron Therapy ◽  
Deficiency Anemia ◽  
Oral Iron Therapy

scholarly journals Reply: Intravenous Ferumoxytol in Pediatric Patients With Iron-Deficiency Anemia

2017 ◽  
Vol 51 (12) ◽  
pp. 1146-1146
Author(s):  
Nabil E. Hassan
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Pediatric Patients ◽  
Iron Absorption ◽  
Deficiency Anemia

Iron Deficiency in children is common problem. Its mechanism could be nutritional or due to lack of iron absorption. Several conditions are associated with IDA. Presence of inflammation further complicate attempts to make a definitive diagnoses or accurately quantify reponse to therapy.

Iron Amino Acid Chelates

2004 ◽  
Vol 74 (6) ◽  
pp. 435-443 ◽  
Author(s):  
Hertrampf ◽  
Olivares
Keyword(s):  
Amino Acid ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Iron Absorption ◽  
Iron Status ◽  
Deficiency Anemia ◽  
Efficacy Trials ◽  
Food Matrices ◽  
The Cost

Iron amino acid chelates, such as iron glycinate chelates, have been developed to be used as food fortificants and therapeutic agents in the prevention and treatment of iron deficiency anemia. Ferrous bis-glycine chelate (FeBC), ferric tris-glycine chelate, ferric glycinate, and ferrous bis-glycinate hydrochloride are available commercially. FeBC is the most studied and used form. Iron absorption from FeBC is affected by enhancers and inhibitors of iron absorption, but to a lesser extent than ferrous sulfate. Its absorption is regulated by iron stores. FeBC is better absorbed from milk, wheat, whole maize flour, and precooked corn flour than is ferrous sulfate. Supplementation trials have demonstrated that FeBC is efficacious in treating iron deficiency anemia. Consumption of FeBC-fortified liquid milk, dairy products, wheat rolls, and multi-nutrient beverages is associated with an improvement of iron status. The main limitations to the widespread use of FeBC in national fortification programs are the cost and the potential for promoting organoleptic changes in some food matrices. Additional research is required to establish the bioavailability of FeBC in different food matrices. Other amino acid chelates should also be evaluated. Finally there is an urgent need for more rigorous efficacy trials designed to define the relative merits of amino acid chelates when compared with bioavailable iron salts such as ferrous sulfate and ferrous fumarate and to determine appropriate fortification levels

Intestinal expression of genes involved in iron absorption in humans

2002 ◽  
Vol 282 (4) ◽  
pp. G598-G607 ◽  
Author(s):  
Andreas Rolfs ◽  
Herbert L. Bonkovsky ◽  
James G. Kohlroser ◽  
Kristina McNeal ◽  
Ashish Sharma ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Iron Absorption ◽  
Genetic Disorders ◽  
Hereditary Hemochromatosis ◽  
Transferrin Saturation ◽  
High Serum ◽  
Deficiency Anemia ◽  
Dependent Manner ◽  
Expression Levels

Hereditary hemochromatosis (HHC) is one of the most frequent genetic disorders in humans. In healthy individuals, absorption of iron in the intestine is tightly regulated by cells with the highest iron demand, in particular erythroid precursors. Cloning of intestinal iron transporter proteins provided new insight into mechanisms and regulation of intestinal iron absorption. The aim of this study was to assess whether, in humans, the two transporters are regulated in an iron-dependent manner and whether this regulation is disturbed in HHC. Using quantitative PCR, we measured mRNA expression of divalent cation transporter 1 (DCT1), iron-regulated gene 1 (IREG1), and hephaestin in duodenal biopsy samples of individuals with normal iron levels, iron-deficiency anemia, or iron overload. In controls, we found inverse relationships between the DCT1 splice form containing an iron-responsive element (IRE) and blood hemoglobin, serum transferrin saturation, or ferritin. Subjects with iron-deficiency anemia showed a significant increase in expression of the spliced form, DCT1(IRE) mRNA. Similarly, in subjects homozygous for the C282Y HFE mutation, DCT1(IRE) expression levels remained high despite high serum iron saturation. Furthermore, a significantly increased IREG1 expression was observed. Hephaestin did not exhibit a similar iron-dependent regulation. Our data show that expression levels of human DCT1 mRNA, and to a lesser extent IREG1 mRNA, are regulated in an iron-dependent manner, whereas mRNA of hephaestin is not affected. The lack of appropriate downregulation of apical and basolateral iron transporters in duodenum likely leads to excessive iron absorption in persons with HHC.

scholarly journals Mutation of the gastric hydrogen-potassium ATPase alpha subunit causes iron-deficiency anemia in mice

Blood ◽  
2011 ◽  
Vol 118 (24) ◽  
pp. 6418-6425 ◽  
Author(s):  
Lara Krieg ◽  
Oren Milstein ◽  
Philippe Krebs ◽  
Yu Xia ◽  
Bruce Beutler ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Iron Absorption ◽  
Osmotic Fragility ◽  
Microcytic Anemia ◽  
Deficiency Anemia ◽  
Α Subunit ◽  
Hypochromic Microcytic Anemia ◽  
Gastric Proton Pump ◽  
Potassium Atpase

Abstract Iron is an essential component of heme and hemoglobin, and therefore restriction of iron availability directly limits erythropoiesis. In the present study, we report a defect in iron absorption that results in iron-deficiency anemia, as revealed by an N-ethyl-N-nitrosourea–induced mouse phenotype called sublytic. Homozygous sublytic mice develop hypochromic microcytic anemia with reduced osmotic fragility of RBCs. The sublytic phenotype stems from impaired gastrointestinal iron absorption caused by a point mutation of the gastric hydrogen-potassium ATPase α subunit encoded by Atp4a, which results in achlorhydria. The anemia of sublytic homozygotes can be corrected by feeding with a high-iron diet or by parenteral injection of iron dextran; rescue can also be achieved by providing acidified drinking water to sublytic homozygotes. These findings establish the necessity of the gastric proton pump for iron absorption and effective erythropoiesis.

Iron deficiency anemia: A comprehensive review on iron absorption, bioavailability and emerging food fortification approaches

2020 ◽  
Vol 99 ◽  
pp. 58-75 ◽  
Author(s):  
Kumar Shubham ◽  
T. Anukiruthika ◽  
Sayantani Dutta ◽  
A.V. Kashyap ◽  
Jeyan A. Moses ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Iron Absorption ◽  
Deficiency Anemia ◽  
Food Fortification ◽  
Comprehensive Review

Management and predictors of early mortality in elderly patients with iron deficiency anemia: a prospective study of 111 patients

2007 ◽  
Vol 31 (2) ◽  
pp. 169-174 ◽  
Author(s):  
Stéphane Nahon ◽  
Pierre Lahmek ◽  
Nazmye ARAS ◽  
Cécile Poupardin ◽  
Bruno Lesgourgues ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Elderly Patients ◽  
Prospective Study ◽  
Iron Deficiency Anemia ◽  
Early Mortality ◽  
Deficiency Anemia ◽  
A Prospective Study

scholarly journals Ferric Gluconate Complex in Elderly Hospital Inpatients without Terminal Kidney Failure

2018 ◽  
Vol 71 (3) ◽  
Author(s):  
Patrick Viet-Quoc Nguyen ◽  
Judith Latour
Keyword(s):  
Iron Deficiency ◽  
Elderly Patients ◽  
Iron Deficiency Anemia ◽  
Kidney Failure ◽  
Iron Supplementation ◽  
Adverse Reactions ◽  
Deficiency Anemia ◽  
Patients Âgés ◽  
Parenteral Iron ◽  
Taux D’Hémoglobine

<p><strong>ABSTRACT</strong></p><p><strong>Background: </strong>Anemia is a common health issue for elderly patients. For patients with iron deficiency who cannot tolerate iron supplementation by the oral route, the parenteral route may be used. Options for parenteral iron supplementation include ferric gluconate complex (FGC).</p><p><strong>Objectives: </strong>To evaluate the safety of FGC in elderly patients without terminal kidney failure and to assess its efficacy in treating iron-deficiency anemia.</p><p><strong>Methods: </strong>An observational chart review was conducted at a tertiary care university health centre. Patients included in the study were 65 years of age or older, had received at least 1 dose of FGC between January 1, 2014, and December 31, 2015, and had a hemoglobin count of less than 130 g/L (men) or less than 120 g/L (women) at baseline. For each patient, the observation period began when the first dose of FGC was administered and ended 60 days after the last dose. The main safety outcome (occurrence of any adverse reaction) was evaluated for every patient, with the efficacy analysis being limited to patients with a diagnosis of iron deficiency anemia.</p><p><strong>Results: </strong>A total of 144 patients were included in the study, of whom 76 had iron-deficiency anemia. No serious, life-threatening adverse reactions were reported. The most commonly reported adverse reactions were nausea and vomiting. The mean increase in hemoglobin count was 13.5 g/L, a statistically significant change from baseline.</p><p><strong>Conclusions: </strong>These results show that FGC is safe for use in elderly patients, with very few mild adverse reactions. Use of FGC led to increased hemoglobin count within 60 days. Of the 3 options for parenteral iron supplementation available in Canada, iron sucrose has not been studied in elderly patients, and iron dextran has a higher incidence of anaphylaxis, whereas FGC appears to be a safe alternative for patients with intolerance to oral iron.</p><p><strong>RÉSUMÉ</strong></p><p><strong>Contexte : </strong>L’anémie est un problème de santé courant chez les patients âgés. Les patients qui présentent une carence en fer et une intolérance à la prise de suppléments de fer par la voie orale peuvent être traités par voie parentérale. Le complexe de gluconate ferrique de sodium (CGFS) représente l’une des options d’apport complémentaire en fer par voie parentérale.</p><p><strong>Objectifs : </strong>Évaluer l’innocuité du CGFS chez le patient âgé qui n’est pas atteint d’insuffisance rénale terminale et évaluer son efficacité dans le traitement de l’anémie ferriprive.</p><p><strong>Méthodes : </strong>Une analyse observationnelle a été menée au moyen des dossiers médicaux dans un établissement de santé universitaire de soins tertiaires. Les patients dont le dossier médical a été retenu pour l’analyse étaient âgés de 65 ans ou plus, avaient reçu au moins une dose de CGFS entre le 1er janvier 2014 et le 31 décembre 2015 et présentaient initialement un taux d’hémoglobine de moins de 130 g/L (hommes) ou de moins de 120 g/L (femmes). Pour chaque patient, la période d’observation s’étendait du moment où la première dose de CGFS avait été administrée au soixantième jour suivant la dernière dose. Le principal paramètre d’évaluation de l’innocuité (survenue de toute reaction indésirable) faisait l’objet d’une évaluation pour chaque patient. L’analyse de l’efficacité se limitait aux patients ayant reçu un diagnostic d’anémie ferriprive.</p><p><strong>Résultats : </strong>Au total, 144 patients ont été admis à l’étude et, parmi eux, 76 présentaient une anémie ferriprive. Aucune réaction indésirable grave menaçant la vie du patient n’a été notée. Les réactions indésirables les plus souvent signalées étaient des nausées et des vomissements. L’augmentation moyenne des taux d’hémoglobine était de 13,5 g/L, un changement statistiquement significatif comparé à la valeur de départ.</p><p><strong>Conclusions : </strong>Les résultats montrent que le CGFS est sécuritaire pour le patient âgé et qu’il ne provoque que très peu de réactions indésirables légères. L’emploi du CGFS a produit une augmentation des taux d’hémoglobine en moins de 60 jours. Parmi les 3 options d’apport complémentaire en fer pris par voie parentérale disponibles au Canada, le fer-saccharose n’a pas été étudié auprès de patients âgés et le fer-dextran est associé à une plus grande incidence de cas d’anaphylaxie; or, le CGFS semble être une solution sécuritaire pour les patients qui présentent une intolérance au fer administré par voie orale.</p>

scholarly journals Respiratory infections drive hepcidin-mediated blockade of iron absorption leading to iron deficiency anemia in African children

2019 ◽  
Vol 5 (3) ◽  
pp. eaav9020 ◽  
Author(s):  
Andrew M. Prentice ◽  
Amat Bah ◽  
Momodou W. Jallow ◽  
Amadou T. Jallow ◽  
Saikou Sanyang ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Iron Absorption ◽  
Respiratory Infections ◽  
Fecal Calprotectin ◽  
Deficiency Anemia ◽  
Low Grade ◽  
Reactive Protein ◽  
African Children ◽  
Low Grade Inflammation

Iron deficiency anemia (IDA) is the most prevalent nutritional condition worldwide. We studied the contribution of hepcidin-mediated iron blockade to IDA in African children. We measured hepcidin and hemoglobin weekly, and hematological, inflammatory, and iron biomarkers at baseline, 7 weeks, and 12 weeks in 407 anemic (hemoglobin < 11 g/dl), otherwise healthy Gambian children (6 to 27 months). Each child maintained remarkably constant hepcidin levels (P < 0.0001 for between-child variance), with half consistently maintaining levels that indicate physiological blockade of iron absorption. Hepcidin was strongly predicted by nurse-ascribed adverse events with dominant signals from respiratory infections and fevers (all P < 0.0001). Diarrhea and fecal calprotectin were not associated with hepcidin. In multivariate analysis, C-reactive protein was the dominant predictor of hepcidin and contributed to iron blockade even at very low levels. We conclude that even low-grade inflammation, especially associated with respiratory infections, contributes to IDA in African children.

Sign in / Sign up

Export Citation Format

Share Document